QUINTESSENTIAL-2

A Phase 3 Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-Exposed Multiple Myeloma

Near Add Your Location

Sorting 19 by

Medical College of Wisconsin
Froedtert Hospital
Milwaukee, WI
  • Accepting patients
MUSC Hollings Cancer Center
Medical University of South Carolina
Charleston, SC
  • Not yet accepting
UCLA Medical Center, Santa Monica
UCLA Health
Santa Monica, CA
  • Accepting patients
Weill Cornell
New York, NY
  • Accepting patients
Cleveland Clinic - Taussig Cancer Center
Taussig Cancer Institute
Cleveland, OH
  • Accepting patients
Baptist MD Anderson
Jacksonville, FL
  • Accepting patients
Huntsman Cancer Institute
University of Utah
Salt Lake City, UT
  • Accepting patients
  • Show Principal Investigator

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.